Lithium influences brain signalling involved in mood regulation and is used mainly for Bipolar Disorder. Lithium tablets are prescribed for long-term mood stabilisation, relapse prevention, and selected acute episodes, with dosing adjusted individually and supported by blood, kidney, and thyroid monitoring.
Lithium is a mineral-derived psychiatric medication and a Mood Stabilizer used primarily in established Bipolar Disorder. Prescription products contain lithium salts, most commonly lithium carbonate or lithium citrate, although the exact salt and release pattern determine how the tablets are used.
The amount per intake is set individually for each person rather than being one fixed number. Clinicians consider the lithium salt, immediate-release or extended-release formulation, treatment phase, age, kidney function, response, and interacting medicines.
Lithium dosage is usually adjusted gradually. A blood sample is commonly timed in relation to the last tablet so that the result reflects a clinically interpretable concentration. The laboratory and prescribing team determine the precise sampling instructions.
Initial treatment may use a cautious prescribed dose, followed by adjustment after the body reaches a more stable concentration. Maintenance dosing may differ from the amount used during an acute manic episode.
Patients should:
The helpful lithium concentration is close to the harmful concentration. That is why a person can feel stable on one dose and develop toxicity after dehydration, a new interacting medicine, or a sudden change in kidney function.
Repeat testing may be needed after dose changes, illness, substantial changes in fluid or salt intake, and the introduction or discontinuation of medicines that affect lithium clearance.
Lithium is a mineral-derived psychiatric medication and a Mood Stabilizer used primarily in established Bipolar Disorder. Prescription products contain lithium salts, most commonly lithium carbonate or lithium citrate, although the exact salt and release pattern determine how the tablets are used. Lithium is recognised as a first-line option for long-term maintenance therapy because it can reduce the risk of recurrent manic and depressive episodes.
The benefit comes with a narrow therapeutic index. This means the blood concentration that produces benefit lies relatively close to the concentration that can cause toxicity. Health Canada product information describes the need for individual dosing and laboratory follow-up during treatment [1].
Prescription lithium and low-dose products containing lithium orotate cannot be compared by the milligram number alone. One label may describe the mass of the entire lithium compound, while another may describe elemental lithium. The two figures do not represent the same thing.
Lithium changes intracellular signalling inside nerve cells and influences several neurotransmitter systems involved in mood regulation. Its action is biologically broad rather than a simple increase or decrease in one chemical messenger.
The exact mechanism remains complex. Lithium affects signalling pathways linked to neuronal resilience, second messengers, gene expression, and communication between brain cells. Dopamine is one neurotransmitter system influenced indirectly, but lithium should not be described as a straightforward dopamine-lowering medicine.
The clinical result is reduced mood instability for many people with Bipolar Disorder. Maintenance treatment can lower the chance of new manic episodes and may reduce depressive recurrence, though response varies between individuals.
Lithium influences neuronal signalling without correcting a single confirmed “chemical imbalance.” This distinction matters because treatment response depends on the person’s diagnosis, episode pattern, kidney function, other medicines, and adherence.
The practical outcome is more useful than attempting to reduce lithium to one neurotransmitter pathway. Blood monitoring remains necessary because cellular effects and blood concentration are related, but they are not identical measures.
The World Health Organization identifies bipolar illness as a condition requiring ongoing, individualised care rather than short courses chosen without clinical assessment [2].
Lithium may be prescribed for:
Lithium is prescribed for a diagnosed mood disorder, not for ordinary mood fluctuations, occasional stress, or normal changes in motivation. Its preventive benefit develops through continued treatment rather than a single calming effect.
The most preventable problems involve treating lithium like an ordinary tablet. It is not appropriate to borrow another person’s dose, use a supplement label as a dosing guide, or assume that a familiar pain reliever is harmless.
Patients also sometimes stop lithium when they feel well. Feeling well may indicate that maintenance treatment is working, not that treatment is no longer needed.
Lithium may not be for you if regular blood tests, kidney or thyroid monitoring, and consistent fluid and salt intake cannot be maintained safely.
Common lithium effects include thirst, increased urination, fine hand tremor, nausea, loose stools, and weight change. Some effects improve after the body adapts or after a clinician adjusts the dose, but persistent or worsening symptoms need review.
Possible effects include:
A fine tremor can occur at therapeutic concentrations. A new coarse tremor, especially with weakness or confusion, is more concerning.
One practical detail is easy to miss: vomiting and diarrhoea can raise lithium exposure even when the prescribed dose has not changed. Fluid loss reduces the body’s ability to clear lithium.
Possible toxicity symptoms include worsening tremor, repeated vomiting or diarrhoea, marked weakness, drowsiness, confusion, slurred speech, blurred vision, unsteady walking, muscle twitching, or poor coordination.
Severe symptoms require urgent medical assessment. Do not take extra tablets to compensate for a missed intake, and do not stop long-term treatment abruptly without medical direction unless an emergency clinician tells you to do so.
Long-term lithium may contribute to reduced thyroid function, changes in kidney concentrating ability, and, rarely, more serious kidney impairment. These risks vary by person and are managed through medical history, laboratory tests, and dose review.
Lithium is one option within treatment plans for Bipolar Disorder. Other Mood Stabilizer approaches include selected anticonvulsant medicines and Antipsychotics, each with different evidence, monitoring needs, and risks.
| Treatment category | Main clinical considerations | Key monitoring issues |
|---|---|---|
| Lithium | Strong maintenance role for selected patients; useful in recurrent mania | Lithium Plasma Level, kidney function, thyroid function |
| Anticonvulsant mood stabilisers | Choice depends on episode pattern, comorbidities, and reproductive considerations | Liver, blood counts, drug-specific tests, or clinical review |
| Antipsychotics | May treat acute mania, depression, psychosis, or support maintenance | Weight, glucose, lipids, movement symptoms, sedation |
Lithium and Antipsychotics may be complementary rather than direct substitutes. Treatment selection depends on previous response, dominant manic or depressive pattern, kidney and thyroid status, pregnancy considerations, other illnesses, and patient preference.
No single Mood Stabiliser is suitable for every person. Lithium’s monitoring burden is substantial, while alternatives carry their own metabolic, neurological, hepatic, haematological, or reproductive risks.
In clinical practice, prescribers usually describe lithium as a long-term treatment requiring a partnership between symptom tracking and laboratory monitoring. The goal is not simply to increase the dose until mood changes; the goal is to maintain a concentration that balances relapse prevention with tolerability. Clinicians review symptoms alongside laboratory results. They also reassess hydration, interacting medicines, and adherence during follow-up. This approach helps distinguish treatment response from emerging toxicity.
A physician will usually ask about kidney disease, thyroid disease, pregnancy plans, breastfeeding, heart rhythm problems, sodium intake, fluid intake, and all prescription and non-prescription products. These details influence the starting plan and the frequency of follow-up.
One useful clinical observation is that a stable routine helps interpretation. If tablet timing, hydration, diet, and blood-test timing change together, it becomes harder to identify why a lithium level or symptom pattern has shifted.
Yes. Lithium can cause tremor, dizziness, drowsiness, blurred vision, or reduced coordination, especially after initiation or a dose change. Health Canada product information (2024) supports caution until the individual response is clear, especially before driving or operating machinery. Avoid these activities if concentration, balance, alertness, or vision is impaired.
Lithium may be used in adolescents in selected psychiatric circumstances, but treatment requires specialist assessment and closer attention to growth, kidney function, thyroid function, hydration, and adherence. Health Canada (2024) and the Canadian Paediatric Society (2023) emphasise age-specific prescribing decisions rather than applying adult routines automatically. A person under 18 should not start, stop, or adjust lithium without the responsible clinician’s direction.
Discuss kidney disease, thyroid problems, heart disease, pregnancy or breastfeeding, low-salt diets, recurrent dehydration, and every prescription, over-the-counter, and supplement product. The European Medicines Agency (2024) highlights the importance of reviewing interacting medicines and monitoring requirements before treatment begins. Mention NSAIDs, ACE inhibitors, ARBs, diuretics, Magnesium, Zinc, and any history of severe vomiting or diarrhoea.
The answer depends on the tablet formulation. Extended-release tablets generally must not be crushed or chewed because that can release lithium too quickly, while some immediate-release tablets may have different handling instructions. Health Canada product information (2024) should guide the specific formulation; swallowing difficulty should be discussed with the prescribing team before altering a tablet.
Do not increase Lithium Dosage independently or add Lithium Orotate as a substitute. The prescriber may review the diagnosis, adherence, tablet timing, Lithium Plasma Level, thyroid function, kidney function, sleep, substance use, and other treatments. NICE guidance (2023) supports reviewing the treatment plan when relapse symptoms persist, worsen, or return despite prescribed therapy.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used Lithium at my prescribed dose for several weeks as part of my long-term bipolar treatment. My mood swings were less disruptive and I was able to keep a steadier routine at work. I was satisfied with the improvement.
Lithium reduced the severe highs for me at my prescribed dose, but the benefit was gradual over several weeks. I noticed more thirst and had to plan around blood tests, so it was helpful with a few practical inconveniences.
Lithium did not give me the improvement I hoped for after several weeks at the prescribed dose. I developed worsening tremor and nausea, stopped taking it after discussing the problem with my doctor, and moved to a different treatment plan.
After staying on my prescribed Lithium schedule for several weeks, I felt more emotionally even and missed fewer days of normal activities. The change was steady rather than sudden, which suited me.
Lithium at my prescribed dose helped reduce the repeated mood swings that had interrupted my plans after several weeks of treatment. I appreciated having a clear monitoring routine and felt more stable after the treatment had been established.
